Plasma cell leukemia
disease diseaseOn this page
Also known as leukaemia plasmacyticleukemia plasmacyticleukemia, plasma cellPCLplasmacytic leukaemiaplasmacytic leukemia
Summary
Plasma cell leukemia (MONDO:0018689) is a cancer and 57 clinical trials. Top therapeutic interventions include fludarabine phosphate, ixazomib citrate, and plerixafor. A subtype of plasma cell neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
- Clinical trials: 57
Clinical features
Epidemiology
Prevalence records
1 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Annual incidence | <1 / 1 000 000 | 0.04 | Europe | Validated |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | plasma cell leukemia |
| Mondo ID | MONDO:0018689 |
| EFO | EFO:0006475 |
| MeSH | D007952 |
| Orphanet | 454714 |
| DOID | DOID:9513 |
| ICD-10-CM | C90.1 |
| ICD-11 | 2048216430 |
| NCIT | C3180 |
| SNOMED CT | 95210003 |
| UMLS | C0023484 |
| MedGen | 9733 |
| GARD | 0009373 |
| Is cancer (heuristic) | yes |
Also known as: leukaemia plasmacytic · leukemia plasmacytic · leukemia, plasma cell · PCL · plasma cell leukemia · plasmacytic leukaemia · plasmacytic leukemia
Disease family
This is a subtype of plasma cell neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › plasma cell neoplasm › plasma cell leukemia
Related subtypes (6): refractory plasma cell neoplasm, plasmacytoma, leukemoid reaction, plasma cell myeloma, non-amyloid monoclonal immunoglobulin deposition disease, heavy chain disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
11 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Bortezomib | Phase 2 |
| Busulfan | Phase 2 |
| Daratumumab | Phase 2 |
| Dexamethasone | Phase 2 |
| Doxorubicin | Phase 2 |
| Elotuzumab | Phase 2 |
| Ixazomib Citrate | Phase 2 |
| Lenalidomide | Phase 2 |
| Melphalan | Phase 2 |
| Panobinostat | Phase 2 |
| Pomalidomide | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 57.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 23 |
| Not specified | 11 |
| PHASE1 | 10 |
| PHASE1/PHASE2 | 8 |
| EARLY_PHASE1 | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03314974 | PHASE2 | RECRUITING | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
| NCT05054478 | PHASE2 | NOT_YET_RECRUITING | Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation |
| NCT05092451 | PHASE1/PHASE2 | RECRUITING | Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances |
| NCT05405387 | PHASE2 | RECRUITING | Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant |
| NCT05805605 | PHASE2 | RECRUITING | Allo HSCT Using RIC and PTCy for Hematological Diseases |
| NCT05870917 | PHASE2 | RECRUITING | A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia |
| NCT05979363 | PHASE2 | RECRUITING | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia |
| NCT06140966 | PHASE2 | RECRUITING | Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma |
| NCT06333509 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL |
| NCT06517017 | PHASE2 | RECRUITING | Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma |
| NCT06636552 | PHASE2 | RECRUITING | An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L |
| NCT06830733 | PHASE2 | NOT_YET_RECRUITING | Study to Evaluate the Safety and Efficacy of ARI0002h, for the Initial Treatment of Patients With Primary Plasma Cell Leukaemia |
| NCT07109323 | PHASE1/PHASE2 | RECRUITING | Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM |
| NCT07509086 | PHASE2 | RECRUITING | IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia |
| NCT07523555 | PHASE1/PHASE2 | RECRUITING | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies |
| NCT07605416 | PHASE2 | NOT_YET_RECRUITING | Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial |
| NCT00027820 | PHASE1/PHASE2 | COMPLETED | Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
| NCT00307086 | PHASE2 | COMPLETED | Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants |
| NCT00615589 | PHASE2 | TERMINATED | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen |
| NCT00821249 | PHASE1/PHASE2 | COMPLETED | A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma |
| NCT01008462 | PHASE2 | COMPLETED | Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia |
| NCT01328236 | PHASE2 | UNKNOWN | Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia |
| NCT01435720 | PHASE1/PHASE2 | UNKNOWN | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) |
| NCT01553357 | PHASE2 | COMPLETED | Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia |
| NCT01658904 | PHASE1/PHASE2 | TERMINATED | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma |
| NCT01729091 | PHASE2 | COMPLETED | Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma |
| NCT02506959 | PHASE2 | COMPLETED | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma |
| NCT02547662 | PHASE2 | COMPLETED | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia |
| NCT02556931 | PHASE2 | COMPLETED | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
| NCT02661035 | PHASE2 | COMPLETED | Allo HSCT Using RIC for Hematological Diseases |
| NCT02722668 | PHASE2 | COMPLETED | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
| NCT02334865 | PHASE1 | ACTIVE_NOT_RECRUITING | SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy |
| NCT05219721 | PHASE1 | RECRUITING | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
| NCT05759793 | PHASE1 | RECRUITING | A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
| NCT05823571 | PHASE1 | ACTIVE_NOT_RECRUITING | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients |
| NCT06655519 | PHASE1 | NOT_YET_RECRUITING | An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia |
| NCT01163357 | PHASE1 | COMPLETED | Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma |
| NCT01372540 | PHASE1 | COMPLETED | Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia |
| NCT02315157 | PHASE1 | WITHDRAWN | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma |
| NCT02504359 | PHASE1 | COMPLETED | Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 11 |
| IXAZOMIB CITRATE | 4 | 2 |
| PLERIXAFOR | 4 | 2 |
| TECLISTAMAB | 4 | 2 |
| CARFILZOMIB | 4 | 1 |
| CILTACABTAGENE AUTOLEUCEL | 4 | 1 |
| ELOTUZUMAB | 4 | 1 |
| ELRANATAMAB | 4 | 1 |
| IDECABTAGENE VICLEUCEL | 4 | 1 |
| ISATUXIMAB | 4 | 1 |
| PANOBINOSTAT | 4 | 1 |
| POMALIDOMIDE | 4 | 1 |
| TALQUETAMAB | 4 | 1 |
| VENETOCLAX | 4 | 1 |
| INCOMPLETE FREUND’S ADJUVANT | 3 | 1 |
| ITACITINIB | 3 | 1 |
| FILANESIB | 2 | 2 |
| SVN53-67/M57-KLH PEPTIDE VACCINE | 2 | 1 |
| CHEMBL1813256 | 0 | 2 |
| CHEMBL5204484 | 0 | 1 |
| CHEMBL344227 | 0 | 1 |
| CHEMBL2093113 | 0 | 1 |